{"protocolSection": {"identificationModule": {"nctId": "NCT03736629", "orgStudyIdInfo": {"id": "IRB17-1287"}, "organization": {"fullName": "University of Chicago", "class": "OTHER"}, "briefTitle": "Azithromycin Treatment for the Airway Microbiome in Asthma", "officialTitle": "The AZITRAMBA Trial: Azithromycin Treatment for the Airway Microbiome in Asthma"}, "statusModule": {"statusVerifiedDate": "2023-08", "overallStatus": "TERMINATED", "whyStopped": "Inability to accrue patients, particularly after COVID pandemic.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-03-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-06-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-11-07", "studyFirstSubmitQcDate": "2018-11-08", "studyFirstPostDateStruct": {"date": "2018-11-09", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-11-23", "resultsFirstSubmitQcDate": "2023-08-03", "resultsFirstPostDateStruct": {"date": "2023-08-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-08-03", "lastUpdatePostDateStruct": {"date": "2023-08-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Chicago", "class": "OTHER"}, "collaborators": [{"name": "Northwestern University", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms."}, "conditionsModule": {"conditions": ["Asthma Chronic"], "keywords": ["Asthma", "Azithromycin", "Microbiome", "Sputum"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 17, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "8 weeks of placebo capsule once daily by mouth", "interventionNames": ["Drug: Placebo"]}, {"label": "Azithromycin", "type": "ACTIVE_COMPARATOR", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth", "interventionNames": ["Drug: Azithromycin"]}, {"label": "Non-asthmatic controls", "type": "NO_INTERVENTION", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "interventions": [{"type": "DRUG", "name": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) once daily by mouth", "armGroupLabels": ["Azithromycin"], "otherNames": ["Zithromax"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control Test (ACT) Score Change From Baseline Over 8 Weeks", "description": "Score ranging from 0 to 40 indicating the degree of asthma symptoms. Lower score indicating worse asthma symptoms.", "timeFrame": "Baseline and 8 weeks"}], "secondaryOutcomes": [{"measure": "Forced Expiratory Volume (FEV1) Change From Baseline Over 8 Weeks", "description": "Volume of air exhaled in 1 second on a forced expiration, expressed as percent of predicted, indicating the degree of airflow obstruction in asthma", "timeFrame": "8 weeks"}, {"measure": "Sputum Eosinophils Change From Baseline Over 8 Weeks", "description": "Percentage of 'eosinophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Sputum Neutrophils Change From Baseline Over 8 Weeks", "description": "Percentage of 'neutrophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Number of Participants With Diary Event or Serious Asthma Exacerbation Over 8 Weeks", "description": "The outcome is derived from a weighted scoring system called CompEx that describes asthma symptoms recorded on a daily basis. Final result is a dichotomous outcome indicating whether the patient had a \"diary event\" based on changes in peak expiratory flow, reliever use, and asthma symptoms or a serious exacerbation (deterioration of asthma leading to oral corticosteroid use, emergency room admission, or hospital admission).", "timeFrame": "8 weeks"}, {"measure": "Microbiome Shannon Alpha-diversity Score Change From Baseline to 8 Weeks", "description": "A measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma", "timeFrame": "8 weeks"}, {"measure": "Microbiome Beta-diversity Score Change From Baseline to 8 Weeks", "description": "A second measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma", "timeFrame": "8 weeks"}, {"measure": "Microbiome Change in Relative Proportion of Top 10 Genera From Baseline to 8 Weeks", "description": "A measure of how many of the top types of bacteria are present in the sputum or oral sample. Value changes with asthma", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria (All participants):\n\n1. Age 18 - 55 years\n2. Able to provide informed consent\n3. Smoking history \\< 10 pack-years\n\nInclusion Criteria for subjects with poorly controlled asthma\n\n1. Methacholine PC20 \\< 16 mg/ml or PD 20 \\< 400 mcg/ml or albuterol response \\> 12% on FEV1 after 4 puffs of albuterol\n2. Currently prescribed ICS + LABA\n3. Meet definition for Th2-low asthma: peripheral blood eosinophil count \\< 300 and exhaled nitric oxide level \\< 30 ppb.\n\nExclusion Criteria (All participants)\n\n1. History of allergy or intolerance to any medications used in this study\n2. Medication exclusions:\n\n   1. Current use of medications that prolong QTc interval\n   2. Current use of omalizumab or other ant-IgE therapies\n   3. Current use of anti-IL 5 therapies\n   4. Current use of anticoagulants\n3. Prednsione or other oral steroids within past 3 months\n4. Pregnancy or lactation, or plans to become pregnant\n5. Other respiratory or inflammatory disorders (e.g., sarcoidosis, emphysema)\n6. Pre-existing liver disease by history\n7. Smoking within the last 6 months\n8. Exacerbation of asthma in past 3 months\n9. Affected by a hearing disorder\n10. Clinically significant medical condition (e.g., heart failure, seizure disorder) which may in-crease risk as determined by study investigator\n11. Corrected QT interval \\> 450 msec. Patients with known cardiac history or prolonged QT interval on a screening EKG are excluded given the small but real potential for macrolide-related side effects", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Steve White, MD", "affiliation": "University of Chicago", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60201", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}]}, "referencesModule": {"references": [{"pmid": "33032168", "type": "RESULT", "citation": "Vogelmeier CF, Fuhlbrigge A, Jauhiainen A, Scheepers LEJM, Bengtsson T, Peterson S, Karlsson N, Sethi T, Locantore N, Tal-Singer R, Rennard S, Fageras M, Da Silva CA. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respir Med. 2020 Nov;173:106175. doi: 10.1016/j.rmed.2020.106175. Epub 2020 Sep 28."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "We will share individual participant data that is de-identified available to all qualified investigators", "infoTypes": ["STUDY_PROTOCOL", "ICF", "CSR"], "timeFrame": "Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database (e.g., sequencing information will be deposited in a genetics bio-bank).", "accessCriteria": "All qualified investigators who sign appropriate data use agreements and material transfer agreements with the University of Chicago and Northwestern University"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "FG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "FG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "BG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "BG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "17"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.5", "lowerLimit": "42", "upperLimit": "59"}, {"groupId": "BG001", "value": "47.4", "lowerLimit": "45", "upperLimit": "49"}, {"groupId": "BG002", "value": "35.5", "lowerLimit": "19", "upperLimit": "54"}, {"groupId": "BG003", "value": "39.5", "lowerLimit": "19", "upperLimit": "59"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "8"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control Test (ACT) Score Change From Baseline Over 8 Weeks", "description": "Score ranging from 0 to 40 indicating the degree of asthma symptoms. Lower score indicating worse asthma symptoms.", "populationDescription": "Outcome variable is not applicable to non-asthmatic controls, as they were not assessed for asthma symptoms.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.67"}, {"groupId": "OG001", "value": "0.00", "spread": "2.00"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Study did not reach its accrual goal. Sample size is too small to draw any conclusions.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.72", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.14", "ciUpperLimit": "4.81", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.72"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume (FEV1) Change From Baseline Over 8 Weeks", "description": "Volume of air exhaled in 1 second on a forced expiration, expressed as percent of predicted, indicating the degree of airflow obstruction in asthma", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of predicted", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.67", "spread": "3.76"}, {"groupId": "OG001", "value": "-4.00", "spread": "11.00"}, {"groupId": "OG002", "value": "-2.92", "spread": "1.37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.59", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-5.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.98", "ciUpperLimit": "24.65", "estimateComment": "Study did not reach its accrual goal. Sample size is too small to draw any conclusions."}]}, {"type": "SECONDARY", "title": "Sputum Eosinophils Change From Baseline Over 8 Weeks", "description": "Percentage of 'eosinophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation", "populationDescription": "Some patients had missing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "percentage of eosinophils", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.00"}, {"groupId": "OG002", "value": "0.06", "lowerLimit": "-0.33", "upperLimit": "0.64"}]}]}]}, {"type": "SECONDARY", "title": "Sputum Neutrophils Change From Baseline Over 8 Weeks", "description": "Percentage of 'neutrophils', an inflammatory cell seen in the airways of people with asthma, indicating the degree of inflammation", "populationDescription": "Some patients had missing data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "percentage of neutrophils", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00", "lowerLimit": "-0.00", "upperLimit": "-0.00"}, {"groupId": "OG001", "value": "1.59", "lowerLimit": "1.59", "upperLimit": "1.59"}, {"groupId": "OG002", "value": "-10.03", "lowerLimit": "-46.88", "upperLimit": "8.03"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Diary Event or Serious Asthma Exacerbation Over 8 Weeks", "description": "The outcome is derived from a weighted scoring system called CompEx that describes asthma symptoms recorded on a daily basis. Final result is a dichotomous outcome indicating whether the patient had a \"diary event\" based on changes in peak expiratory flow, reliever use, and asthma symptoms or a serious exacerbation (deterioration of asthma leading to oral corticosteroid use, emergency room admission, or hospital admission).", "populationDescription": "Outcome measure is not applicable to non-asthmatic controls, as they were not assessed for asthma severity.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Study did not reach its accrual goal. Sample size is too small to draw any conclusions.", "nonInferiorityType": "SUPERIORITY", "pValue": "1.0", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Microbiome Shannon Alpha-diversity Score Change From Baseline to 8 Weeks", "description": "A measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma", "populationDescription": "Insufficient sample size for meaningful results in intervention arms due to low accrual. Microbiome assays were not performed.", "reportingStatus": "POSTED", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Microbiome Beta-diversity Score Change From Baseline to 8 Weeks", "description": "A second measure of the diversity of the bacteria in the sputum or oral sample; that is, how many different types of bacteria are present. This value decreases in severe asthma", "populationDescription": "Insufficient sample size for meaningful results in intervention arms. Microbiome assays were not performed.", "reportingStatus": "POSTED", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Microbiome Change in Relative Proportion of Top 10 Genera From Baseline to 8 Weeks", "description": "A measure of how many of the top types of bacteria are present in the sputum or oral sample. Value changes with asthma", "populationDescription": "Insufficient sample size for meaningful results in intervention arms. Microbiome assays were not performed.", "reportingStatus": "POSTED", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo"}, {"id": "OG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth"}, {"id": "OG002", "title": "Non-asthmatic Controls", "description": "Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "14 weeks Note: Adverse events were not collected in the Non-asthmatic controls.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "8 weeks of placebo capsule once daily by mouth\n\nPlacebo: Placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 2, "otherNumAtRisk": 3}, {"id": "EG001", "title": "Azithromycin", "description": "8 weeks of Azithromycin (250 mg) capsule once daily by mouth\n\nAzithromycin: 8 weeks of Azithromycin (250 mg) once daily by mouth", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}], "otherEvents": [{"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Bruising", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Early termination leading to small numbers of subjects analyzed."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Theodore Karrison (Research Professor)", "organization": "University of Chicago", "email": "tkarrison@health.bsd.uchicago.edu", "phone": "773-702-9326"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-10-31", "uploadDate": "2022-10-25T15:07", "filename": "Prot_SAP_000.pdf", "size": 404478}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-12-22", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017963", "term": "Azithromycin"}], "ancestors": [{"id": "D000000900", "term": "Anti-Bacterial Agents"}, {"id": "D000000890", "term": "Anti-Infective Agents"}], "browseLeaves": [{"id": "M20132", "name": "Azithromycin", "asFound": "Treat", "relevance": "HIGH"}, {"id": "M4222", "name": "Anti-Bacterial Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}